- Home
- LDWY vs PTIX Comparison
LDWY vs PTIX Comparison
Compare LDWY & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- PTIX
- Stock Information
- Founded
- LDWY 1990
- PTIX 1994
- Country
- LDWY United States
- PTIX United States
- Employees
- LDWY N/A
- PTIX N/A
- Industry
- LDWY Advertising
- PTIX Biotechnology: Pharmaceutical Preparations
- Sector
- LDWY Consumer Discretionary
- PTIX Health Care
- Exchange
- LDWY Nasdaq
- PTIX Nasdaq
- Market Cap
- LDWY 7.2M
- PTIX 6.3M
- IPO Year
- LDWY 1991
- PTIX 2016
- Fundamental
- Price
- LDWY $3.88
- PTIX $2.06
- Analyst Decision
- LDWY
- PTIX
- Analyst Count
- LDWY 0
- PTIX 0
- Target Price
- LDWY N/A
- PTIX N/A
- AVG Volume (30 Days)
- LDWY 20.0K
- PTIX 73.5K
- Earning Date
- LDWY 11-10-2025
- PTIX 11-28-2025
- Dividend Yield
- LDWY N/A
- PTIX N/A
- EPS Growth
- LDWY N/A
- PTIX N/A
- EPS
- LDWY 0.70
- PTIX N/A
- Revenue
- LDWY $69,769,000.00
- PTIX N/A
- Revenue This Year
- LDWY N/A
- PTIX N/A
- Revenue Next Year
- LDWY N/A
- PTIX N/A
- P/E Ratio
- LDWY $5.26
- PTIX N/A
- Revenue Growth
- LDWY 121.91
- PTIX N/A
- 52 Week Low
- LDWY $3.43
- PTIX $1.83
- 52 Week High
- LDWY $6.19
- PTIX $14.28
- Technical
- Relative Strength Index (RSI)
- LDWY 39.52
- PTIX 34.39
- Support Level
- LDWY $3.54
- PTIX $1.83
- Resistance Level
- LDWY $4.10
- PTIX $2.11
- Average True Range (ATR)
- LDWY 0.45
- PTIX 0.18
- MACD
- LDWY -0.05
- PTIX -0.01
- Stochastic Oscillator
- LDWY 8.04
- PTIX 21.74
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in industries: Specialty Ag, consisting of the Bloomia business.
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.